U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT07492108) titled 'Neuromodulation With Percutaneous Electrical Nerve Field Stimulation' on Nov. 24, 2025.
Brief Summary: The IB-Stim is the first device to be approved by the Food and Drug Administration (FDA) for the treatment of functional abdominal pain in adolescents aged 11-18 with IBS. However, the efficacy of Percutaneous electrical nerve field stimulation (PENFS) in adults with gastroparesis like symptoms (GPLS) is not currently known. This study is a double-blind, randomized, sham-controlled pilot study evaluating the efficacy of PENFS using IB-Stim in adult patients with GPLS. A secondary aim will be to assess whether treatment with PENFS ...